Pardes Biosciences, Inc.

NasdaqGM:PRDS Stock Report

Mkt Cap: US$110.9m

Pardes Biosciences Management

Management criteria checks 1/4

Pardes Biosciences' CEO is Tom Wiggans, appointed in Mar 2022, he has a tenure of 1.25 years. His total yearly compensation is $5.26M , comprised of 9.9% salary and 90.1% bonuses, including company stock and options. He directly owns 0.083% of the company’s shares, worth $92.50K. The average tenure of the management team and the board of directors is 2.3 years and 2.2 years respectively.

Key information

Tom Wiggans

Chief executive officer

US$5.3m

Total compensation

CEO salary percentage9.9%
CEO tenure1.3yrs
CEO ownership0.08%
Management average tenure2.3yrs
Board average tenure2.2yrs

Recent management updates

Recent updates

Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation

Jan 20
Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation

We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully

Oct 01
We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully

Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19

Sep 13

Pardes Biosciences GAAP EPS of -$0.48

Aug 15

Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans

Jun 14
Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans

Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform

Jan 21

CEO Compensation Analysis

How has Tom Wiggans's remuneration changed compared to Pardes Biosciences's earnings?
DateTotal Comp.SalaryCompany Earnings
Mar 31 2023n/an/a

-US$93m

Dec 31 2022US$5mUS$521k

-US$97m

Compensation vs Market: Tom's total compensation ($USD5.26M) is above average for companies of similar size in the US market ($USD749.64K).

Compensation vs Earnings: Insufficient data to compare Tom's compensation with company performance.


CEO

Tom Wiggans (71 yo)

1.3yrs

Tenure

US$5,255,958

Compensation

Mr. Thomas G. Wiggans, also known as Tom, serves as Independent Director at CymaBay Therapeutics, Inc. since April 2021. He serves as an Executive Chairman of Follica, Inc. since January 2021. He serves as...


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Wiggans
CEO & Chairman of the Board1.3yrsUS$5.26m0.083%
$ 92.5k
Uri Lopatin
Founder & Directorno dataUS$3.52m9.47%
$ 10.5m
Heidi Henson
Chief Financial Officer2.4yrsUS$1.82m0.53%
$ 586.0k
Elizabeth Lacy
General Counsel & Corporate Secretary2.4yrsno data0.35%
$ 390.7k
Sean Brusky
Chief Business Officer2.1yrsno data0.035%
$ 38.9k

2.3yrs

Average Tenure

56yo

Average Age

Experienced Management: PRDS's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Wiggans
CEO & Chairman of the Board1.3yrsUS$5.26m0.083%
$ 92.5k
Uri Lopatin
Founder & Director3.3yrsUS$3.52m9.47%
$ 10.5m
James Tananbaum
Director2.4yrsUS$110.69kno data
Mark Auerbach
Independent Director2.4yrsUS$170.69k0.12%
$ 130.2k
Michael Varney
Independent Director & Member of Scientific Advisory Board2.8yrsUS$153.69k0.12%
$ 130.2k
J. Lobell
Independent Director2.4yrsUS$163.19k2.27%
$ 2.5m
John Pottage
Independent Directorless than a yearUS$147.00k0%
$ 0
Laura Hamill
Independent Director1.9yrsUS$161.19k0%
$ 0
Laurie Smaldone Alsup
Lead Independent Directorless than a yearUS$146.94k0%
$ 0
Deborah Autor
Independent Director1.9yrsUS$153.69k0%
$ 0
Brad Jenkins
Member of Commercial Advisory Boardno datano datano data

2.2yrs

Average Tenure

62.5yo

Average Age

Experienced Board: PRDS's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.